Levodopa/Carbidopa/Entacapon Ratiopharm

Levodopa, Carbidopa, Entacapone, the active ingredients in Levodopa/Carbidopa/Entacapon Ratiopharm, constitute a combination therapy classified as a Parkinson's disease treatment and are presented as oral tablets for oral administration. The formulation provides levodopa as a dopamine precursor, carbidopa to inhibit peripheral decarboxylation, and entacapone to block COMT metabolism, together improving motor control in adults with Parkinson's disease.

GNH USA supplies Levodopa/Carbidopa/Entacapon Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution for patients requiring Parkinson's disease management.

Levodopa/Carbidopa/Entacapon is used in Parkinson's disease therapy to enhance dopaminergic treatment and manage motor fluctuations. - Parkinson's disease (early stage): improves bradykinesia, rigidity and tremor. - Parkinson's disease with motor fluctuations: reduces "off" periods and prolongs levodopa effect. - Advanced Parkinson's disease: provides more consistent dopaminergic stimulation for overall motor control. - Parkinson's disease patients on levodopa monotherapy: serves as an adjunct to improve symptom control. - Parkinson's disease with dyskinesia: helps balance levodopa dosing to minimize involuntary movements.

Levodopa/Carbidopa/Entacapon may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: gastrointestinal upset often occurring at treatment initiation. - Dizziness: light‑headedness, especially when standing quickly. - Orthostatic hypotension: drop in blood pressure upon standing. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure decline requiring medical attention. - Hallucinations or psychosis: visual disturbances or altered perception. - Dyskinesia: involuntary, erratic movements that may affect daily activities.

When prescribing Levodopa/Carbidopa/Entacapon, clinicians should observe several safety measures. - Blood pressure monitoring: check for orthostatic hypotension regularly. - Psychiatric assessment: evaluate for hallucinations or mood changes before and during therapy. - Liver function testing: monitor hepatic enzymes due to metabolism involvement. - Renal impairment adjustment: consider dose modification in patients with reduced kidney function. - Concomitant MAO‑B inhibitors: avoid use together to prevent hypertensive crisis. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapon interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotic drugs (dopamine antagonists): may diminish therapeutic effect. - Certain antihypertensives (alpha‑blockers): can exacerbate orthostatic hypotension.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: may increase risk of serotonin syndrome. - Iron or calcium supplements: can reduce levodopa absorption if taken simultaneously.